St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases (IMAGE)

St. Jude Children's Research Hospital

St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases

Caption

(L to R) Corresponding author Thirumala-Devi Kanneganti, Ph.D., St. Jude Department of Immunology vice-chair and Center of Excellence for Innate Immunity and Inflammation director, with co-first authors Balamurugan Sundaram, Ph.D., and Nagakannan Pandian, Ph.D., St. Jude Department of Immunology.

Credit

Courtesy of St. Jude Children's Research Hospital

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.